These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31010846)

  • 1. Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
    Lahuerta JJ; Jiménez-Ubieto A; Paiva B; Martínez-López J; González-Medina J; López-Anglada L; Cedena MT; Puig N; Oriol A; Blanchard MJ; Ríos R; Martin J; Martínez R; Sureda A; Hernández MT; de la Rubia J; Krsnik I; Cabañas V; Palomera L; Bargay J; Mateos MV; Rosiñol L; San Miguel JF; Blade J
    Blood; 2019 Jun; 133(25):2664-2668. PubMed ID: 31010846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is urine immunofixation electrophoresis necessary for monitoring myeloma patients who have undergone hematopoietic stem cell transplantation?
    Sencar ME; Yıldız A; Haznedar R
    Transfus Apher Sci; 2019 Dec; 58(6):102660. PubMed ID: 31734164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences identified between serum and urine immunofixation electrophoresis.
    Tracy E; Andrews DM; Constantin MA; Zhu Y
    Clin Chim Acta; 2015 Jan; 439():68-70. PubMed ID: 25307209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy.
    Fulton RB; Fernando SL
    Ann Clin Biochem; 2009 Sep; 46(Pt 5):407-12. PubMed ID: 19641008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophoresis test prevalence, requesting patterns, yield and related bone marrow biopsy findings at a South African tertiary hospital: A 5-year retrospective audit.
    Naidoo N; Erasmus RT; Grewal R; Zemlin AE
    S Afr Med J; 2017 Feb; 107(3):270-273. PubMed ID: 28281435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.
    Singhal S; Vickrey E; Krishnamurthy J; Singh V; Allen S; Mehta J
    Blood; 2009 Jul; 114(1):38-9. PubMed ID: 19411633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of urine immunofixation electrophoresis in prognostic evaluation of hematopoietic stem cell transplantation in patients with myeloma.
    Zhu S; Yang C; Li W; Lin M
    Pak J Med Sci; 2022; 38(1):315-319. PubMed ID: 35035446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
    Dytfeld D; Griffith KA; Friedman J; Lebovic D; Harvey C; Kaminski MS; Jakubowiak AJ
    Leuk Lymphoma; 2011 Jul; 52(7):1271-80. PubMed ID: 21699382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
    Davies FE; Forsyth PD; Rawstron AC; Owen RG; Pratt G; Evans PA; Richards SJ; Drayson M; Smith GM; Selby PJ; Child JA; Morgan GJ
    Br J Haematol; 2001 Mar; 112(3):814-9. PubMed ID: 11260088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
    Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
    Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
    Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
    Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis.
    Sečník P; Honsová E; Jabor A; Lavríková P; Franeková J
    Clin Chem Lab Med; 2016 Jun; 54(6):981-4. PubMed ID: 26760309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
    Goicoechea I; Puig N; Cedena MT; Burgos L; Cordón L; Vidriales MB; Flores-Montero J; Gutierrez NC; Calasanz MJ; Ramos MM; Lara-Astiaso D; Vilas-Zornoza A; Alignani D; Rodriguez I; Sarvide S; Alameda D; Garcés JJ; Rodriguez S; Fresquet V; Celay J; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Rios R; Martin-Sanchez J; Martinez-Martinez R; Sarra J; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Martinez-Climent JA; Orfao A; Rosiñol L; Mateos MV; Lahuerta JJ; Blade J; San Miguel J; Paiva B
    Blood; 2021 Jan; 137(1):49-60. PubMed ID: 32693406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria.
    Narita K; Miura D; Tsushima T; Terao T; Kuzume A; Tabata R; Takeuchi M; Matsue K
    Sci Rep; 2021 Jul; 11(1):14956. PubMed ID: 34294772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome.
    Kaddoura M; Binder M; Dingli D; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Kapoor P; Hwa L; Fonder A; Hobbs M; Hayman S; Leung N; Go RS; Lin Y; Gonsalves W; Kourelis T; Warsame R; Kyle RA; Rajkumar V; Kumar S
    Am J Hematol; 2022 Mar; 97(3):267-273. PubMed ID: 34978743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.